PhRMA

OCTOBER 5, 2022

America relies on the U.S. Food & Drug Administration (FDA) to keep pace with the scientific advancements happening every day in labs across the country. That’s why the recently enacted Prescription Drug User Fee Act (PDUFA VII) and Biosimilar User Fee Act (BsUFA III) are both great news for biopharmaceutical innovation and for patients. With these programs reauthorized for another five years, the FDA can continue doing its vital work reviewing medicines.

FDA 302

FDA 302

Drug Topics

OCTOBER 4, 2022

As technology advances in all areas of life, it is no surprise that technology is becoming more prevalent in independent pharmacy.

Independent Pharmacies 251

Independent Pharmacies 251

Pharmacy Times

OCTOBER 7, 2022

New research suggests that MDMA may offer promising benefits to patients with certain unmet psychological treatment needs.

165

165

pharmaphorum

OCTOBER 6, 2022

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public. Originally developed by New Zealand tech company Soul Machines with support of the Qatar Ministry of Health, the first version of the virtual health worker was used to combat misinformation about the pandemic.

Vaccines 145

Vaccines 145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

PhRMA

OCTOBER 4, 2022

Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or indirectly through a family member or friend: mental illness. Mental Illness Awareness Week is an opportunity to raise awareness about the impacts of mental illness and to better understand and educate communities about what it means to face a mental illness, deal with significant moments of stress throughou

Insurance 272

Insurance 272

Drug Topics

OCTOBER 4, 2022

Does the severe flu season in the southern hemisphere hint at a tough season for the north?

226

226

STAT

OCTOBER 4, 2022

A little over a century ago, scientists working in laboratories discovered that microbes were the cause of many epidemics. Once they understood that, they began to put their faith more and more in laboratory science. This major transformation, called the bacteriological revolution, began in the 1880s. During this period, diphtheria was one of the leading causes of death among mostly poor children in New York City.

145

145

PhRMA

OCTOBER 5, 2022

Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high out-of-pocket costs, using programs like copay coupons to help eligible, commercially insured patients afford their out-of-pocket costs. In fact, the share of patients staying on treatment for one year increased by up to 47% when patients used copay coupons.

Insurance 263

Insurance 263

Drug Topics

OCTOBER 4, 2022

Changes to DIR fees are coming. Taking proactive steps can help pharmacies avoid feeling the pinch.

220

220

Pharmacy Times

OCTOBER 7, 2022

There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.

FDA 156

FDA 156

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 3, 2022

A Swedish scientist won the 2022 Nobel Prize in medicine or physiology on Monday for his groundbreaking research into the evolutionary history of humankind. Svante Pääbo, of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, accomplished something widely believed to be impossible: recovering and reading DNA from 40,000-year-old bones.

141

141

PhRMA

OCTOBER 6, 2022

The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally funded clinics. The biopharmaceutical industry has long supported this program, but unfortunately, 340B has strayed far from its purpose, with more and more for-profit health care entities using these discounts for themselves.

Hospitals 254

Hospitals 254

Drug Topics

OCTOBER 3, 2022

It’s more important than ever to keep your team motivated and incentivized.

200

200

Pharmacy Times

OCTOBER 6, 2022

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

153

153

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Drug Store News

OCTOBER 4, 2022

CVS Health Clinical Trial Services was launched in 2021 with the goal of developing and executing a community-centric model for clinical trials.

137

137

PhRMA

OCTOBER 1, 2022

A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and medical innovation. I-MAK accuses biopharmaceutical companies of blocking competition and gaming the system by patenting new innovations, when in reality, new patents do not extend old patents, and they do not prevent competitors from launching new products.

249

249

Drug Topics

OCTOBER 7, 2022

Early interventions might preserve lung function, particularly in younger patients with frequent asthma exacerbations, say authors.

198

198

Pharmacy Times

OCTOBER 7, 2022

The vaccine prevents whooping cough in infants younger than 2 months. It can be safely administered to mothers who are in their third trimester.

Vaccines 149

Vaccines FDA 149

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

OCTOBER 4, 2022

After years spent building a seemingly slapdash set of medical initiatives, Verily seems to have a game plan. The Alphabet life sciences spinout is doubling down on the business of evidence generation , trying to build the tools and technical infrastructure that will help pharma and digital health customers run the next generation of clinical trials.

FDA 128

FDA 128

PhRMA

OCTOBER 7, 2022

PhRMA submitted comments this week in response to the Department of Health & Human Services (HHS) proposed rule on the Nondiscrimination in Health Programs and Activities. As outlined in our comments, PhRMA supports many policies in the proposed rule that aim to combat discrimination in health programs and activities, including broad application of nondiscrimination provisions, promoting health equity and preventing discriminatory benefit designs.

Insurance 186

Insurance 186

Drug Topics

OCTOBER 7, 2022

SingleCare's 4th annual celebration of the best in pharmacy, from pharmacists to pharmacy technicians and teams across the United States has been announced.

187

187

Pharmacy Times

OCTOBER 4, 2022

Understanding long-term frailty trajectories with kidney function measures could help prevent worse adverse health outcomes in older patients.

149

149

STAT

OCTOBER 4, 2022

The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday be remembered as the beginning of a revolution in Alzheimer’s diagnosis and treatment. Years and years of failed Alzheimer’s trials created, and then fortified , doubts about whether drugs that attacked amyloid, a brain protein linked to Alzheimer’s disease, were a valid approach to its treatment.

Pharmaceutical Companies 128

Pharmaceutical Companies Pharmaceutical Companies 128

pharmaphorum

OCTOBER 7, 2022

A UK study has found that Merck & Co’s oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations compared to placebo in patients at higher risk from the virus, adding fuel to assertions in some quarters that its authorisation was premature. The 25,000-subject PANORAMIC trial conducted by researchers at Oxford University looked at the addition of a five-day course of Lagevrio (molnupiravir) to standard care in people aged over 50, or adults aged 18 and over with conditions th

Vaccines 119

Vaccines Labelling Hospitals 119

Drug Topics

OCTOBER 6, 2022

Understanding the main causes and staying current on recommendations and treatments will help reduce patient rates of the condition.

187

187

Pharmacy Times

OCTOBER 1, 2022

This month's generic product news features clorazepate dipotassium tablets, exemestane tablets, and paliperidone extended-release tablets.

149

149

STAT

OCTOBER 6, 2022

The American Revolution had July 4. The allies had D-Day. And now U.S. patients, held down for decades by information hoarders, can rally around a new turning point, October 6, 2022 — the day they got their health data back. Under federal rules taking effect Thursday, health care organizations must give patients unfettered access to their full health records in digital format.

127

127

Pharmaceutical Technology

OCTOBER 7, 2022

Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The agreement aids Provention in leveraging the capabilities and commercial resources of Sanofi to back teplizumab’s launch. The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.

FDA 119

FDA 119

Drug Topics

OCTOBER 4, 2022

OTC Hearing Aids will soon be available, but this access also comes with questions about counseling and ensuring safety.

187

187

Pharmacy Times

OCTOBER 4, 2022

With a trained representative focused on building relationships with prescribers in the community, pharmacies have the opportunity to significantly expand how they do business.

Community Pharmacies 145

Community Pharmacies 145

STAT

OCTOBER 6, 2022

The United States is in a (relative) Covid-19 lull, with cases and hospitalizations falling as the wave driven by the BA.5 lineage of the Omicron variant recedes. But as if we needed a portent of an anticipated fall and winter wave , Covid is on the rise in some European countries. What’s different, at least for now, is that there’s not one variant pushing the wave.

Hospitals 123

Hospitals Vaccines 123

Pharmaceutical Technology

OCTOBER 6, 2022

Pfizer has acquired all the outstanding shares of the common stock of biopharmaceutical firm Global Blood Therapeutics (GBT) in a deal worth nearly $5.4bn. The total enterprise value comprised debt and the net of cash acquired. With the latest acquisition, GBT became a wholly-owned Pfizer subsidiary. GBT discovers and develops life-changing therapies for ailments with an initial focus on sickle cell disease (SCD).

FDA 115

FDA 115

Drug Topics

OCTOBER 1, 2022

The move is meant to expand access to reproductive health care for women in the state.

187

187